Search

BackgroundChildhood acute myeloid leukaemia (AML) is a higly heterogenous disorder. But its clinical characteristics according to ethic groups have been rarely studied.ObjectiveTo explore ethnic-specific clinical characteristics and prognosis of paediatric patients with non-M3 AML from Yunnan province.MethodsPaediatric patients with newly diagnosed non-M3 AML were rectuited from Kunming Children's Hospital between January 1, 2015 and March 1, 2020. Basic baseline clinical data, including demographic characteristics (ethnic group, gender, age) , general information (white blood cell count, haemoglobin, platelet count, lactate dehydrogenase, bone marrow blast cell, FAB classification) , karyotype, and genetic information were collected. All patients were followed up from enrolment to 2020-05-31, and treatment protocols, risk stratifications, and prognoses were collected.ResultsSeventy-two cases〔51 cases of Han, 21 cases of minorities (5 Yi, 4 Hui, 3 Hani, 2 Bai, 2 Miao, 1 Zhuang, 1 Wa, 1 Buyi, 1 Mongolian and 1 Dai) 〕 were enrolled, with a follow-up of 2-60 months. Children of ethnic minorities had higher mean white blood cell count did those of Han (P0.05) . Event-free survival rate and overall survival rate of children of Han were higher than those of children of ethnic minorities (χ2=8.098, P=0.004; χ2=12.547, P

In this study, a pH-responsive polycaprolactone (PCL)–copper peroxide (CuO2) composite antibacterial coating was developed by suspension flame spraying. The successful synthesis of CuO2 nanoparticles and fabrication of the PCL-CuO2 composite coatings were confirmed by microstructural and chemical analysis. The composite coatings were structurally homogeneous, with the chemical properties of PCL well maintained. The acidic environment was found to effectively accelerate the dissociation of CuO2, allowing the simultaneous release of Cu2+ and H2O2. Antimicrobial tests clearly revealed the enhanced antibacterial properties of the PCL-CuO2 composite coating against both Escherichia coli and Staphylococcus aureus under acidic conditions, with a bactericidal effect of over 99.99%. This study presents a promising approach for constructing pH-responsive antimicrobial coatings for biomedical applications. [ABSTRACT FROM AUTHOR]

Copyright of Automatisierungstechnik is the property of De Gruyter and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

The impact of SARS‐CoV‐2 infection shortly after vaccination on vaccine‐induced immunity is unknown, which is also one of the concerns for some vaccinees during the pandemic. Here, based on a cohort of individuals who encountered BA.5 infection within 8 days after receiving the fourth dose of a bivalent mRNA vaccine, preceded by three doses of inactivated vaccines, we show that booster mRNA vaccination provided 48% protection efficacy against symptomatic infections. At Day 7 postvaccination, the level of neutralizing antibodies (Nabs) against WT and BA.5 strains in the uninfected group trended higher than those in the symptomatic infection group. Moreover, there were greater variations in Nabs levels and a significant decrease in virus‐specific CD4+ T cell response observed in the symptomatic infection group. However, symptomatic BA.5 infection significantly increased Nab levels against XBB.1.9.1 and BA.5 (symptomatic > asymptomatic > uninfected group) at Day 10 and resulted in a more gradual decrease in Nabs against BA.5 compared to the uninfected group at Day 90. Our data suggest that BA.5 infection might hinder the early generation of Nabs and the recall of the CD4+ T cell response but strengthens the Nab and virus‐specific T cell response in the later phase. Our data confirmed that infection can enhance host immunity regardless of the short interval between vaccination and infection and alleviate concerns about infections shortly after vaccination, which provides valuable guidance for developing future vaccine administration strategies. [ABSTRACT FROM AUTHOR]